Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Ehlermann

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
International Journal of Cardiology|August 8, 2006
Immediate and chronic effects of AV-delay optimization in patients with cardiac resynchronization therapyStefan E Hardt, Said Hashem Fani Yazdi, Alexander Bauer, et al.
Drug Design, Development and Therapy|March 12, 2015
Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantationMatthias Helmschrott, Rasmus Rivinius, Arjang Ruhparwar, et al.
Scientific Reports|May 3, 2025
Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureusBenedict Morath, Sabrina Klein, Ute Chiriac, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 8, 2014
The "Wagshurst study": p.Val40Ile transthyretin gene variant causes late-onset cardiomyopathyRalf Bauer, Nicola Dikow, Andreas Brauer, et al.
Drug Design, Development and Therapy|September 24, 2014
Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimenMatthias Helmschrott, Jan Beckendorf, Ceylan Akyol, et al.
International Journal of Cardiology. Heart & Vasculature|August 9, 2017
Etiology-specific assessment of predictors of long-term survival in chronic systolic heart failureJennifer Franke, Christian Zugck, Matthias Hochadel, et al.
The Journal of Gene Medicine|April 14, 2004
S100A1 gene transfer: a strategy to strengthen engineered cardiac graftsAndrew Remppis, Sven T Pleger, Patrick Most, et al.
International Journal of Molecular Sciences|October 27, 2022
Genotype Complements the Phenotype: Identification of the Pathogenicity of an LMNA Splice Variant by Nanopore Long-Read Sequencing in a Large DCM FamilyFarbod Sedaghat-Hamedani, Sabine Rebs, Elham Kayvanpour, et al.
Drug Design, Development and Therapy|May 1, 2013
Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantationIbrahim Gueler, Susanne Mueller, Matthias Helmschrott, et al.
The Journal of Biological Chemistry|May 2, 2003
The C terminus (amino acids 75-94) and the linker region (amino acids 42-54) of the Ca2+-binding protein S100A1 differentially enhance sarcoplasmic Ca2+ release in murine skinned skeletal muscle fibersPatrick Most, Andrew Remppis, Cornelia Weber, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
International Journal of Cardiology|August 8, 2006
Immediate and chronic effects of AV-delay optimization in patients with cardiac resynchronization therapyStefan E Hardt, Said Hashem Fani Yazdi, Alexander Bauer, et al.
Drug Design, Development and Therapy|March 12, 2015
Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantationMatthias Helmschrott, Rasmus Rivinius, Arjang Ruhparwar, et al.
Scientific Reports|May 3, 2025
Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureusBenedict Morath, Sabrina Klein, Ute Chiriac, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 8, 2014
The "Wagshurst study": p.Val40Ile transthyretin gene variant causes late-onset cardiomyopathyRalf Bauer, Nicola Dikow, Andreas Brauer, et al.
Drug Design, Development and Therapy|September 24, 2014
Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimenMatthias Helmschrott, Jan Beckendorf, Ceylan Akyol, et al.
International Journal of Cardiology. Heart & Vasculature|August 9, 2017
Etiology-specific assessment of predictors of long-term survival in chronic systolic heart failureJennifer Franke, Christian Zugck, Matthias Hochadel, et al.
The Journal of Gene Medicine|April 14, 2004
S100A1 gene transfer: a strategy to strengthen engineered cardiac graftsAndrew Remppis, Sven T Pleger, Patrick Most, et al.
International Journal of Molecular Sciences|October 27, 2022
Genotype Complements the Phenotype: Identification of the Pathogenicity of an LMNA Splice Variant by Nanopore Long-Read Sequencing in a Large DCM FamilyFarbod Sedaghat-Hamedani, Sabine Rebs, Elham Kayvanpour, et al.
Drug Design, Development and Therapy|May 1, 2013
Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantationIbrahim Gueler, Susanne Mueller, Matthias Helmschrott, et al.
The Journal of Biological Chemistry|May 2, 2003
The C terminus (amino acids 75-94) and the linker region (amino acids 42-54) of the Ca2+-binding protein S100A1 differentially enhance sarcoplasmic Ca2+ release in murine skinned skeletal muscle fibersPatrick Most, Andrew Remppis, Cornelia Weber, et al.
Pageof 9